MS MBA - Boundless Bio Chief Officer
| BOLD Stock | USD 1.17 0.02 1.74% |
Executive
MS MBA is Chief Officer of Boundless Bio Common
| Age | 52 |
| Address | 10955 Alexandria Way, San Diego, CA, United States, 92121 |
| Phone | 858 766 9912 |
| Web | https://boundlessbio.com |
Boundless Bio Management Efficiency
The company has return on total asset (ROA) of (0.2466) % which means that it has lost $0.2466 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4488) %, meaning that it created substantial loss on money invested by shareholders. Boundless Bio's management efficiency ratios could be used to measure how well Boundless Bio manages its routine affairs as well as how well it operates its assets and liabilities. As of February 27, 2026, Return On Tangible Assets is expected to decline to -0.3. In addition to that, Return On Capital Employed is expected to decline to -0.35. At present, Boundless Bio's Debt To Assets are projected to increase slightly based on the last few years of reporting.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Linda Mahoney | Phio Pharmaceuticals Corp | N/A | |
| MBA ACA | Adial Pharmaceuticals | 63 | |
| Esq JD | Cardio Diagnostics Holdings | 60 | |
| CPA BSc | Aprea Therapeutics | 64 | |
| MPH MD | Aprea Therapeutics | N/A | |
| Brigitte MD | Adial Pharmaceuticals | 62 | |
| Lars Abrahmsen | Aprea Therapeutics | 69 | |
| Brian Wiley | Aprea Therapeutics | 58 | |
| MD FACS | Aprea Therapeutics | 56 | |
| Brigitte Roberston | Adial Pharmaceuticals | N/A | |
| Khullani JD | Cardio Diagnostics Holdings | 41 | |
| Michel Afargan | Aprea Therapeutics | N/A | |
| Abel CPA | Adial Pharmaceuticals | N/A | |
| Andrew Taubman | Adial Pharmaceuticals | N/A | |
| Lisa Carson | Phio Pharmaceuticals Corp | 59 | |
| Melissa CPA | Kiora Pharmaceuticals | 46 | |
| Stefan Sperl | Kiora Pharmaceuticals | N/A | |
| Brigette MD | Adial Pharmaceuticals | 61 | |
| John JD | Adial Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -0.45 | ||||
| Return On Asset | -0.25 |
Boundless Bio Common Leadership Team
Elected by the shareholders, the Boundless Bio's board of directors comprises two types of representatives: Boundless Bio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Boundless. The board's role is to monitor Boundless Bio's management team and ensure that shareholders' interests are well served. Boundless Bio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Boundless Bio's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christian Hassig, Chief Officer | ||
| James MD, Interim Officer | ||
| Jamilu Rubin, Chief Officer | ||
| Shailaja Kasibhatla, Senior Development | ||
| Peter Krein, Senior Medicine | ||
| Anthony Pinkerton, Senior Discovery | ||
| Amy Berkley, Senior Team | ||
| MS MBA, Chief Officer | ||
| Jessica JD, Chief Secretary | ||
| Meredith Wesley, Senior Culture | ||
| Zachary Hornby, President CEO | ||
| Sara Weymer, Senior Operations | ||
| David Hinkle, Controller Finance | ||
| Jonathan MD, CoFounder Chairman |
Boundless Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Boundless Bio a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.45 | ||||
| Return On Asset | -0.25 | ||||
| Current Valuation | (41.4 M) | ||||
| Shares Outstanding | 22.39 M | ||||
| Shares Owned By Insiders | 11.39 % | ||||
| Shares Owned By Institutions | 51.21 % | ||||
| Number Of Shares Shorted | 7.88 K | ||||
| Price To Earning | (7.22) X | ||||
| Price To Book | 0.24 X | ||||
| EBITDA | (64.28 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Boundless Bio Common is a strong investment it is important to analyze Boundless Bio's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Boundless Bio's future performance. For an informed investment choice regarding Boundless Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Boundless Bio Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Will Biotechnology sector continue expanding? Could Boundless diversify its offerings? Factors like these will boost the valuation of Boundless Bio. Projected growth potential of Boundless fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Boundless Bio data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
The market value of Boundless Bio Common is measured differently than its book value, which is the value of Boundless that is recorded on the company's balance sheet. Investors also form their own opinion of Boundless Bio's value that differs from its market value or its book value, called intrinsic value, which is Boundless Bio's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Boundless Bio's market value can be influenced by many factors that don't directly affect Boundless Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Boundless Bio's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Boundless Bio should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Boundless Bio's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.